-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Clovis Oncology (NASDAQ:CLVS) Short Interest Up 14.4% in September
Clovis Oncology (NASDAQ:CLVS) Short Interest Up 14.4% in September
Clovis Oncology (NASDAQ:CLVS – Get Rating) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 33,160,000 shares, an increase of 14.4% from the August 31st total of 28,990,000 shares. Based on an average trading volume of 8,440,000 shares, the days-to-cover ratio is currently 3.9 days.
Clovis Oncology Price Performance
Shares of NASDAQ:CLVS traded down $0.01 during midday trading on Monday, reaching $1.19. 76,310 shares of the company were exchanged, compared to its average volume of 9,633,150. The business's fifty day moving average is $1.34 and its two-hundred day moving average is $1.53. Clovis Oncology has a one year low of $0.58 and a one year high of $4.76.
Get Clovis Oncology alerts:Clovis Oncology (NASDAQ:CLVS – Get Rating) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.09). During the same quarter last year, the company posted ($0.61) EPS. As a group, sell-side analysts expect that Clovis Oncology will post -1.74 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. First Republic Investment Management Inc. purchased a new position in Clovis Oncology in the 1st quarter worth about $27,000. Mirabella Financial Services LLP purchased a new position in Clovis Oncology during the 1st quarter valued at about $36,000. Sassicaia Capital Advisers LLC purchased a new position in Clovis Oncology during the 1st quarter valued at about $40,000. Teacher Retirement System of Texas increased its position in Clovis Oncology by 34.3% during the 4th quarter. Teacher Retirement System of Texas now owns 21,456 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 5,479 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new position in Clovis Oncology during the 4th quarter valued at about $64,000. Hedge funds and other institutional investors own 29.47% of the company's stock.Clovis Oncology Company Profile
(Get Rating)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Read More
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Near-Term Headwinds Send Nike To The Bargain Basement
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- Is the Bond Market Signaling a Market Bottom?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Clovis Oncology (NASDAQ:CLVS – Get Rating) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 33,160,000 shares, an increase of 14.4% from the August 31st total of 28,990,000 shares. Based on an average trading volume of 8,440,000 shares, the days-to-cover ratio is currently 3.9 days.
克洛維斯腫瘤學公司(納斯達克代碼:CLVS-GET評級)是9月份空頭股數銷量大幅增長的接受者。截至9月15日,空頭股數共有3316萬股,比8月31日的2899萬股增加了14.4%。以平均成交量8,440,000股計算,目前天數與回補比率為3.9天。
Clovis Oncology Price Performance
Clovis腫瘤學價格表現
Shares of NASDAQ:CLVS traded down $0.01 during midday trading on Monday, reaching $1.19. 76,310 shares of the company were exchanged, compared to its average volume of 9,633,150. The business's fifty day moving average is $1.34 and its two-hundred day moving average is $1.53. Clovis Oncology has a one year low of $0.58 and a one year high of $4.76.
納斯達克:CLVS的股價週一午盤下跌0.01美元,至1.19美元。該公司成交量為76,310股,而其平均成交量為9,633,150股。該業務的50日移動均線切入位在1.34美元,200日移動均線切入位在1.53美元。Clovis Oncology的一年低點為0.58美元,一年高位為4.76美元。
Clovis Oncology (NASDAQ:CLVS – Get Rating) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.09). During the same quarter last year, the company posted ($0.61) EPS. As a group, sell-side analysts expect that Clovis Oncology will post -1.74 earnings per share for the current fiscal year.
克洛維斯腫瘤公司(納斯達克代碼:CLVS-GET Rating)最近一次發佈季度收益數據是在8月8日星期一。這家生物製藥公司公佈了該季度每股收益(0.50美元),低於普遍預期的(0.41美元)和(0.09美元)。去年同期,該公司公佈的每股收益為0.61美元。賣方分析師預計,Clovis Oncology本財年的每股收益將達到1.74美元。
Institutional Inflows and Outflows
機構資金流入和流出
Clovis Oncology Company Profile
Clovis腫瘤學公司簡介
(Get Rating)
(獲取評級)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Clovis Oncology,Inc.是一家生物製藥公司,專注於在美國、歐洲和國際上收購、開發抗癌藥物並將其商業化。其商業產品包括Rubra(Rucaparib)片劑,這是一種小分子聚ADP-核糖聚合酶抑制劑,用於單一療法治療與惡性BRCA突變相關的晚期卵巢癌患者,這些患者已接受兩種或兩種以上化療,並由FDA批准的Rubra輔助診斷選擇進行治療。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Near-Term Headwinds Send Nike To The Bargain Basement
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- Is the Bond Market Signaling a Market Bottom?
- 免費獲取StockNews.com關於克洛維斯腫瘤學(CLVS)的研究報告
- 近期的逆風將耐克送到了廉價地下室
- 阿徹·丹尼爾斯·米德蘭:49年增長的紅利英雄
- 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎?
- 麥格納國際是您的汽車和電動汽車一站式庫存
- 債券市場是否發出了市場觸底的信號?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受Clovis腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Clovis Oncology和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧